Merus Announces Financial Results for the First Quarter and Provides Business Update
Both posters present preclinical data demonstrating that the Dock & Block\xc2\xae activity of Zeno can potently inhibit NRG1 (and NRG1 fusion) signaling through HER3:HER2 and tumorigenesis.
- Both posters present preclinical data demonstrating that the Dock & Block\xc2\xae activity of Zeno can potently inhibit NRG1 (and NRG1 fusion) signaling through HER3:HER2 and tumorigenesis.
- MCLA-129 is a Biclonics\xc2\xae, which binds to EGFR and c-MET and is being investigated for the treatment of solid tumors.
- Dr. Geuijen has over two decades of experience in discovering and developing antibodies as medicines for clinical evaluation.
- Merus received an upfront cash payment of $40 million, as well as an equity investment by Lilly of $20 million in Merus common shares.